.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Accenture
Cantor Fitzgerald
AstraZeneca
Merck
Mallinckrodt
Baxter
UBS
Chinese Patent Office
Federal Trade Commission

Generated: November 20, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022406

« Back to Dashboard
NDA 022406 describes XARELTO, which is a drug marketed by Janssen Pharms and is included in one NDA. It is available from two suppliers. There are five patents protecting this drug and one Paragraph IV challenge. Additional details are available on the XARELTO profile page.

The generic ingredient in XARELTO is rivaroxaban. There are thirty-one drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the rivaroxaban profile page.

Summary for 022406

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:5
Formulation / Manufacturing:see details

Pharmacology for NDA: 022406

Mechanism of ActionFactor Xa Inhibitors

Medical Subject Heading (MeSH) Categories for 022406

Suppliers and Packaging for NDA: 022406

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
XARELTO
rivaroxaban
TABLET;ORAL 022406 NDA Janssen Pharmaceuticals, Inc. 50458-580 50458-580-10 10 BLISTER PACK in 1 CARTON (50458-580-10) > 10 TABLET, FILM COATED in 1 BLISTER PACK
XARELTO
rivaroxaban
TABLET;ORAL 022406 NDA Janssen Pharmaceuticals, Inc. 50458-580 50458-580-30 30 TABLET, FILM COATED in 1 BOTTLE (50458-580-30)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength10MG
Approval Date:Jul 1, 2011TE:RLD:Yes
Regulatory Exclusivity Expiration:Jul 1, 2016
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:► SubscribePatent Expiration:Aug 28, 2024Product Flag?YSubstance Flag?YDelist Request?
Patented Use:TREATMENT OF DEEP VEIN THROMBOSIS (DVT)
Patent:► SubscribePatent Expiration:Aug 28, 2024Product Flag?YSubstance Flag?YDelist Request?
Patented Use:TREATMENT OF PULMONARY EMBOLISM (PE)


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
AstraZeneca
Express Scripts
UBS
Chubb
Daiichi Sankyo
Mallinckrodt
Federal Trade Commission
Baxter
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot